6533b82ffe1ef96bd12952bb
RESEARCH PRODUCT
Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Frank BirkleinMartin WinterhollerTanja SchlerethIrini MoukaGabi Eisenbarthsubject
AdultMalemedicine.medical_specialtyBotulinum ToxinsTime FactorsInjections SubcutaneousSweatingBotulinum toxin aCellular and Molecular NeuroscienceMedicineHumansBotulinum toxin type BAnhidrosisBotulinum Toxins Type AHypohidrosisDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryStarchBotulinum toxinSurgerySudomotorDose–response relationshipThreshold doseNeuromuscular AgentsAnesthesiaFemaleNeurology (clinical)medicine.symptombusinessBotulinum toxin typemedicine.drugFollow-Up Studiesdescription
Abstract Background Botulinum toxin type A (BoNT/A) is 20–50 times more effective than Botulinum toxin type B (BoNT/B) concerning the treatment of muscular hypercontractions [Sloop, R.R., Cole, B.A., Escutin, R.O., 1997. Human response to botulinum toxin injection: type B compared with type A. Neurology 49, 189–194]. Botulinum toxins block motor nerves as well as autonomic fibres [Rand, M.J., Whaler, B.C., 1965. Impairment of sympathetic transmission by botulinum toxin. Nature 206, 588–591]. Objective Purpose of this study was to analyse the dose dependent reduction of sweating using the BoNT/A preparation Botox® and to compare the results with our earlier results analysing Dysport® [Braune, C., Erbguth, F., Birklein, F., 2001. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br. J. Dermatol. 144, 111–117] and Neurobloc® (BoNT/B) [Birklein, F., Eisenbarth, G., Erbguth, F., Winterholler, M., 2003. Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J. Invest. Dermatol. 121, 1312–1316]. Methods Different doses of Botox® were injected subcutaneously (n=27 healthy subjects). Planimetrical analyses of the area of anhidrosis and quantitative sudomotor-axon-reflex testing (QSART) were done after 3 weeks, 3 and 6 months. Results A threshold dose of 1.25 MU Botox® led to anhidrotic skin spots after 3 weeks. The duration of anhidrosis was prolonged for 3 months when 17.5 MU and for 6 months when 50 MU were injected. Anhidrotic area size decreased with time (p=0.001), indicating partial recovery at the edges. After 3 weeks, QSART had significantly decreased to 29% of baseline. With doses of 70 MU or more it decreased to zero. After 3 months, QSART had returned to 68% of baseline and after 6 months to 87%. Conclusions Botox® dose-dependently suppressed sweating. Comparison to Dysport® and Neurobloc® revealed a strikingly similar efficacy after 3 weeks and 3 months for all preparations. BoNT/A in general induced a more sustained anhidrosis than BoNT/B.
year | journal | country | edition | language |
---|---|---|---|---|
2004-05-27 | Autonomic neuroscience : basicclinical |